- Home
- PLSE vs ELVN Comparison
PLSE vs ELVN Comparison
Compare PLSE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | ELVN |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | ELVN |
|---|---|---|
| Price | $52.77 | $54.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $22.00 | ★ $43.40 |
| AVG Volume (30 Days) | 531.6K | ★ 783.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $14.79 |
| 52 Week High | $58.90 | $62.32 |
Technical Indicators
Market Signals| Indicator | PLSE | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 67.23 | 41.82 |
| Support Level | $24.27 | $25.63 |
| Resistance Level | N/A | $62.16 |
| Average True Range (ATR) | 3.85 | 1.95 |
| MACD | -0.21 | -0.59 |
| Stochastic Oscillator | 63.42 | 1.93 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.